<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;ff=20230829180705&amp;v=2.17.9.post6+86293ac&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;fc=20230708114047
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;ff=20230829180705&amp;v=2.17.9.post6+86293ac&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;fc=20230708114047" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.17.9.post6+86293ac)</generator>
<language>en</language>
<lastbuilddate>Tue, 29 Aug 2023 22:07:06 +0000</lastbuilddate>
<pubDate>Tue, 29 Aug 2023 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Initiating Mineralocorticoid Antagonists for Longstanding Heart Failure With Reduced Ejection Fraction: Better Late Than Never?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37642609/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230829180705&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 1:S0735-1097(23)06074-6. doi: 10.1016/j.jacc.2023.06.022. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37642609/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829180705&v=2.17.9.post6+86293ac">37642609</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.022>10.1016/j.jacc.2023.06.022</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37642609</guid>
<pubDate>Tue, 29 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Andrew J Sauer</dc:creator>
<dc:creator>Judith Hsia</dc:creator>
<dc:date>2023-08-29</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Initiating Mineralocorticoid Antagonists for Longstanding Heart Failure With Reduced Ejection Fraction: Better Late Than Never?</dc:title>
<dc:identifier>pmid:37642609</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.022</dc:identifier>
</item>
<item>
<title>Underutilization of Mineralocorticoid Antagonists in Patients With Heart Failure With Reduced Ejection Fraction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37642608/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230829180705&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Patients with longer-standing HFrEF had worse clinical status and a higher rate of events, but the benefit of eplerenone was consistent regardless of HFrEF duration. (A Comparison of Outcomes in Patients in NYHA Class II Heart Failure When Treated With Eplerenone or Placebo in Addition to Standard Heart Failure Medicines [EMPHASIS-HF]; NCT00232180).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 1:S0735-1097(23)06073-4. doi: 10.1016/j.jacc.2023.06.021. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: It is unknown how the efficacy and safety of mineralocorticoid receptor antagonists vary according to duration of heart failure with reduced ejection fraction (HFrEF).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: In this study, we sought to evaluate the safety and efficacy of eplerenone according to duration of HFrEF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In the EMPHASIS-HF trial, 3 patient groups were created according to HFrEF duration: &lt;1 year, 1 to &lt;5 years, and ≥5 years. The primary outcome was the composite of heart failure (HF) hospitalization or cardiovascular death. Outcomes were adjusted for prespecified prognostic variables and examined with the use of Cox regression models.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The numbers of patients in each group were: 975, &lt;1 year; 769, 1 to &lt;5 years; and 988, ≥5 years. Patients with longer-standing HF were older and more frequently had cardiovascular and noncardiovascular comorbidities. The rate of the primary outcome (per 100 person-years) increased with HFrEF duration: 9.8 (95% CI: 8.4-11.4) for &lt;1 year, 13.5 (95% CI: 11.6-15.7) for 1 to &lt;5 years, and 17.6 (95% CI: 15.6-19.8) for ≥5 years. The benefits of eplerenone were consistent across HF duration: HRs for the primary outcome were 0.57 (95% CI: 0.42-0.79) for &lt;1 year, 0.81 (95% CI: 0.60-1.10) for 1 to &lt;5 years, and 0.61 (95% CI: 0.48-0.78) for ≥5 years; P<sub>interaction</sub> = 0.24. The absolute benefit was greatest in the longest-duration group: the number needed to treat for the primary outcome was 14 for &lt;1 year, 13 for 1 to &lt;5 years, and 10 for ≥5 years duration.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Patients with longer-standing HFrEF had worse clinical status and a higher rate of events, but the benefit of eplerenone was consistent regardless of HFrEF duration. (A Comparison of Outcomes in Patients in NYHA Class II Heart Failure When Treated With Eplerenone or Placebo in Addition to Standard Heart Failure Medicines [EMPHASIS-HF]; NCT00232180).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37642608/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829180705&v=2.17.9.post6+86293ac">37642608</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.021>10.1016/j.jacc.2023.06.021</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37642608</guid>
<pubDate>Tue, 29 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Shingo Matsumoto</dc:creator>
<dc:creator>Toru Kondo</dc:creator>
<dc:creator>Pardeep S Jhund</dc:creator>
<dc:creator>Ross T Campbell</dc:creator>
<dc:creator>Karl Swedberg</dc:creator>
<dc:creator>Dirk J van Veldhuisen</dc:creator>
<dc:creator>Stuart J Pocock</dc:creator>
<dc:creator>Bertram Pitt</dc:creator>
<dc:creator>Faiez Zannad</dc:creator>
<dc:creator>John J V McMurray</dc:creator>
<dc:date>2023-08-29</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Underutilization of Mineralocorticoid Antagonists in Patients With Heart Failure With Reduced Ejection Fraction</dc:title>
<dc:identifier>pmid:37642608</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.021</dc:identifier>
</item>
<item>
<title>The ESC Working Group on cardiovascular regenerative and reparative medicine</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37642557/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230829180705&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 29:ehad538. doi: 10.1093/eurheartj/ehad538. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37642557/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829180705&v=2.17.9.post6+86293ac">37642557</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad538>10.1093/eurheartj/ehad538</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37642557</guid>
<pubDate>Tue, 29 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Giulio Pompilio</dc:creator>
<dc:creator>Ricardo Sanz-Ruiz</dc:creator>
<dc:creator>Joost P G Sluijter</dc:creator>
<dc:creator>Stefan Janssens</dc:creator>
<dc:date>2023-08-29</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The ESC Working Group on cardiovascular regenerative and reparative medicine</dc:title>
<dc:identifier>pmid:37642557</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad538</dc:identifier>
</item>
<item>
<title>Incorporating principles from commercial advertising into cardiovascular health promotion efforts</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37642214/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230829180705&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 29:ehad537. doi: 10.1093/eurheartj/ehad537. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37642214/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829180705&v=2.17.9.post6+86293ac">37642214</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad537>10.1093/eurheartj/ehad537</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37642214</guid>
<pubDate>Tue, 29 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>David J T Campbell</dc:creator>
<dc:creator>Raj Pannu</dc:creator>
<dc:creator>Braden J Manns</dc:creator>
<dc:date>2023-08-29</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Incorporating principles from commercial advertising into cardiovascular health promotion efforts</dc:title>
<dc:identifier>pmid:37642214</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad537</dc:identifier>
</item>
<item>
<title>S14-Phosphorylated RPN6 Mediates Proteasome Activation by PKA and Alleviates Proteinopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37641975/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230829180705&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: This study establishes in animals that pS14-Rpn6 mediates the activation of 26S proteasomes by PKA and that the reduced pS14-Rpn6 is a key pathogenic factor in cardiac proteinopathy, thereby identifying a new therapeutic target to reduce cardiac proteotoxicity.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Aug 29. doi: 10.1161/CIRCRESAHA.123.322887. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: A better understanding of the regulation of proteasome activities can facilitate the search for new therapeutic strategies. A cell culture study shows that cAMP-dependent PKA (protein kinase A) activates the 26S proteasome by pS14-Rpn6 (serine14-phosphorylated Rpn6), but this discovery and its physiological significance remain to be established in vivo.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Male and female mice with Ser14 of Rpn6 mutated to Ala (S14A [Rpn6/Psmd11<sup>S14A</sup>]) or Asp (S14D) to respectively block or mimic pS14-Rpn6 were created and used along with cells derived from them. cAMP/PKA were manipulated pharmacologically. Ubiquitin-proteasome system functioning was evaluated with the GFPdgn reporter mouse and proteasomal activity assays. Impact of S14A and S14D on proteotoxicity was tested in mice and cardiomyocytes overexpressing the misfolded protein R120G-CryAB (R120G).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: PKA activation increased pS14-Rpn6 and 26S proteasome activities in wild-type but not S14A embryonic fibroblasts (mouse embryonic fibroblasts), adult cardiomyocytes, and mouse hearts. Basal 26S proteasome activities were significantly greater in S14D myocardium and adult mouse cardiomyocytes than in wild-type counterparts. S14D::GFPdgn mice displayed significantly lower myocardial GFPdgn protein but not mRNA levels than GFPdgn mice. In R120G mice, a classic model of cardiac proteotoxicity, basal myocardial pS14-Rpn6 was significantly lower compared with nontransgenic littermates, which was not always associated with reduction of other phosphorylated PKA substrates. Cultured S14D neonatal cardiomyocytes displayed significantly faster proteasomal degradation of R120G than wild-type neonatal cardiomyocytes. Compared with R120G mice, S14D/S14D::R120G mice showed significantly greater myocardial proteasome activities, lower levels of total and K48-linked ubiquitin conjugates, and of aberrant CryAB protein aggregates, less fetal gene reactivation, and cardiac hypertrophy, and delays in cardiac malfunction.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This study establishes in animals that pS14-Rpn6 mediates the activation of 26S proteasomes by PKA and that the reduced pS14-Rpn6 is a key pathogenic factor in cardiac proteinopathy, thereby identifying a new therapeutic target to reduce cardiac proteotoxicity.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37641975/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829180705&v=2.17.9.post6+86293ac">37641975</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.322887>10.1161/CIRCRESAHA.123.322887</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37641975</guid>
<pubDate>Tue, 29 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Liuqing Yang</dc:creator>
<dc:creator>Nirmal Parajuli</dc:creator>
<dc:creator>Penglong Wu</dc:creator>
<dc:creator>Jinbao Liu</dc:creator>
<dc:creator>Xuejun Wang</dc:creator>
<dc:date>2023-08-29</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>S14-Phosphorylated RPN6 Mediates Proteasome Activation by PKA and Alleviates Proteinopathy</dc:title>
<dc:identifier>pmid:37641975</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.322887</dc:identifier>
</item>
<item>
<title>Rare Variant Genetics and Dilated Cardiomyopathy Severity: The DCM Precision Medicine Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37641966/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230829180705&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Advanced DCM was associated with higher odds of rare variants in DCM genes adjudicated as pathogenic or likely pathogenic, compared with individuals with less severe DCM. This finding may help assess the risk of outcomes in management of patients with DCM and their at-risk family members.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Aug 29. doi: 10.1161/CIRCULATIONAHA.123.064847. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Dilated cardiomyopathy (DCM) can lead to advanced disease, defined herein as necessitating a durable left ventricular assist device or a heart transplant (LVAD/HT). DCM is known to have a genetic basis, but the association of rare variant genetics with advanced DCM has not been studied.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We analyzed clinical and genetic sequence data from patients enrolled between 2016 and 2021 in the US multisite DCM Precision Medicine Study, which was a geographically diverse, multiracial, multiethnic cohort. Clinical evaluation included standardized patient interview and medical record query forms. DCM severity was classified into 3 groups: patients with advanced disease with LVAD/HT; patients with an implantable cardioverter defibrillator (ICD) only; or patients with no ICD or LVAD/HT. Rare variants in 36 DCM genes were classified as pathogenic or likely pathogenic or variants of uncertain significance. Confounding factors we considered included demographic characteristics, lifestyle factors, access to care, DCM duration, and comorbidities. Crude and adjusted associations between DCM severity and rare variant genetic findings were assessed using multinomial models with generalized logit link.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Patients' mean (SD) age was 51.9 (13.6) years; 42% were of African ancestry, 56% were of European ancestry, and 44% were female. Of 1198 patients, 347 had LVAD/HT, 511 had an ICD, and 340 had no LVAD/HT or ICD. The percentage of patients with pathogenic or likely pathogenic variants was 26.2%, 15.9%, and 15.0% for those with LVAD/HT, ICD only, or neither, respectively. After controlling for sociodemographic characteristics and comorbidities, patients with DCM with LVAD/HT were more likely than those without LVAD/HT or ICD to have DCM-related pathogenic or likely pathogenic rare variants (odds ratio, 2.3 [95% CI, 1.5-3.6]). The association did not differ by ancestry. Rare variant genetic findings were similar between patients with DCM with an ICD and those without LVAD/HT or ICD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Advanced DCM was associated with higher odds of rare variants in DCM genes adjudicated as pathogenic or likely pathogenic, compared with individuals with less severe DCM. This finding may help assess the risk of outcomes in management of patients with DCM and their at-risk family members.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://www.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CLINICALTRIALS: gov; Unique identifier: NCT03037632.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37641966/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829180705&v=2.17.9.post6+86293ac">37641966</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064847>10.1161/CIRCULATIONAHA.123.064847</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37641966</guid>
<pubDate>Tue, 29 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Mark Hofmeyer</dc:creator>
<dc:creator>Garrie J Haas</dc:creator>
<dc:creator>Elizabeth Jordan</dc:creator>
<dc:creator>Jinwen Cao</dc:creator>
<dc:creator>Evan Kransdorf</dc:creator>
<dc:creator>Gregory A Ewald</dc:creator>
<dc:creator>Alanna A Morris</dc:creator>
<dc:creator>Anjali Owens</dc:creator>
<dc:creator>Brian Lowes</dc:creator>
<dc:creator>Douglas Stoller</dc:creator>
<dc:creator>W H Wilson Tang</dc:creator>
<dc:creator>Sonia Garg</dc:creator>
<dc:creator>Barry H Trachtenberg</dc:creator>
<dc:creator>Palak Shah</dc:creator>
<dc:creator>Salpy V Pamboukian</dc:creator>
<dc:creator>Nancy K Sweitzer</dc:creator>
<dc:creator>Matthew T Wheeler</dc:creator>
<dc:creator>Jane E Wilcox</dc:creator>
<dc:creator>Stuart Katz</dc:creator>
<dc:creator>Stephen Pan</dc:creator>
<dc:creator>Javier Jimenez</dc:creator>
<dc:creator>Frank Smart</dc:creator>
<dc:creator>Jessica Wang</dc:creator>
<dc:creator>Stephen S Gottlieb</dc:creator>
<dc:creator>Daniel P Judge</dc:creator>
<dc:creator>Charles K Moore</dc:creator>
<dc:creator>Gordon S Huggins</dc:creator>
<dc:creator>Daniel D Kinnamon</dc:creator>
<dc:creator>Hanyu Ni</dc:creator>
<dc:creator>Ray E Hershberger</dc:creator>
<dc:creator>DCM Precision Medicine Study of the DCM Consortium</dc:creator>
<dc:date>2023-08-29</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Rare Variant Genetics and Dilated Cardiomyopathy Severity: The DCM Precision Medicine Study</dc:title>
<dc:identifier>pmid:37641966</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.064847</dc:identifier>
</item>
<item>
<title>Cardiac Vagal Nerve Activity Increases During Exercise to Enhance Coronary Blood Flow</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37641938/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230829180705&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Our study demonstrates that cardiac vagal nerve activity actually increases and is crucial for maintaining cardiac function during exercise. Furthermore, our findings show the dynamic modulation of coronary artery blood flow during exercise is mediated by VIP.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Aug 29. doi: 10.1161/CIRCRESAHA.123.323017. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The phrase complete vagal withdrawal is often used when discussing autonomic control of the heart during exercise. However, more recent studies have challenged this assumption. We hypothesized that cardiac vagal activity increases during exercise and maintains cardiac function via transmitters other than acetylcholine.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Chronic direct recordings of cardiac vagal nerve activity, cardiac output, coronary artery blood flow, and heart rate were recorded in conscious adult sheep during whole-body treadmill exercise. Cardiac innervation of the left cardiac vagal branch was confirmed with lipophilic tracer dyes (DiO). Sheep were exercised with pharmacological blockers of acetylcholine (atropine, 250 mg), VIP (vasoactive intestinal peptide; [4Cl-D-Phe6,Leu17]VIP 25 µg), or saline control, randomized on different days. In a subset of sheep, the left cardiac vagal branch was denervated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Neural innervation from the cardiac vagal branch is seen at major cardiac ganglionic plexi, and within the fat pads associated with the coronary arteries. Directly recorded cardiac vagal nerve activity increased during exercise. Left cardiac vagal branch denervation attenuated the maximum changes in coronary artery blood flow (maximum exercise, control: 63.5±5.9 mL/min, n=8; cardiac vagal denervated: 32.7±5.6 mL/min, n=6, <i>P=</i>2.5×10<sup>-</sup><sup>7</sup>), cardiac output, and heart rate during exercise. Atropine did not affect any cardiac parameters during exercise, but VIP antagonism significantly reduced coronary artery blood flow during exercise to a similar level to vagal denervation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our study demonstrates that cardiac vagal nerve activity actually increases and is crucial for maintaining cardiac function during exercise. Furthermore, our findings show the dynamic modulation of coronary artery blood flow during exercise is mediated by VIP.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37641938/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829180705&v=2.17.9.post6+86293ac">37641938</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323017>10.1161/CIRCRESAHA.123.323017</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37641938</guid>
<pubDate>Tue, 29 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Julia Shanks</dc:creator>
<dc:creator>Mridula Pachen</dc:creator>
<dc:creator>Joshua W-H Chang</dc:creator>
<dc:creator>Bindu George</dc:creator>
<dc:creator>Rohit Ramchandra</dc:creator>
<dc:date>2023-08-29</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Cardiac Vagal Nerve Activity Increases During Exercise to Enhance Coronary Blood Flow</dc:title>
<dc:identifier>pmid:37641938</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323017</dc:identifier>
</item>
<item>
<title>Neutrophils for Revascularization Require Activation of CCR6 and CCL20 by TNFα</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37641931/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230829180705&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: We demonstrate that site-specific activation of the CCL20-CCR6 axis via TNFα recruits proangiogenic VEGFA-expressing neutrophils to sites of ischemic injury for initiation of muscle tissue revascularization. The findings provide an attractive option for tissue revascularization, particularly under diabetic conditions.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Aug 29. doi: 10.1161/CIRCRESAHA.123.323071. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Activation of immune-inflammatory pathways involving TNFα (tumor necrosis factor alpha) signaling is critical for revascularization and peripheral muscle tissue repair after ischemic injury. However, mechanisms of TNFα-driven inflammatory cascades directing recruitment of proangiogenic immune cells to sites of ischemia are unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Muscle tissue revascularization after permanent femoral artery ligation was monitored in mutant mice by laser Doppler imaging and light sheet fluorescence microscopy. TNFα-mediated signaling and the role of the CCL20 (C-C motif chemokine ligand 20)-CCR6 (C-C chemokine receptor 6) axis for formation of new vessels was studied in vitro and in vivo using bone marrow transplantation, flow cytometry, as well as biochemical and molecular biological techniques.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: TNFα-mediated activation of tumor necrosis factor receptor TNFR (tumor necrosis factor receptor) 1 but not TNFR2 was found to be required for postischemic muscle tissue revascularization. Bone marrow-derived CCR6<sup>+</sup> neutrophil granulocytes were identified as a previously undescribed TNFα-induced population of proangiogenic neutrophils, characterized by increased expression of VEGFA (vascular endothelial growth factor A). Mechanistically, postischemic activation of TNFR1 induced expression of the CCL20 in vascular cells and promoted translocation of the CCL20 receptor CCR6 to the cell surface of neutrophils, essentially conditioning VEGFA-expressing proangiogenic neutrophils for CCL20-dependent recruitment to sites of ischemia. Moreover, impaired revascularization of ischemic peripheral muscle tissue in diabetic mice was associated with reduced numbers of proangiogenic neutrophils and diminished CCL20 expression. Administration of recombinant CCL20 enhanced recruitment of proangiogenic neutrophils and improved revascularization of diabetic ischemic skeletal muscles, which was sustained by sequential treatment with fluvastatin.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: We demonstrate that site-specific activation of the CCL20-CCR6 axis via TNFα recruits proangiogenic VEGFA-expressing neutrophils to sites of ischemic injury for initiation of muscle tissue revascularization. The findings provide an attractive option for tissue revascularization, particularly under diabetic conditions.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37641931/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829180705&v=2.17.9.post6+86293ac">37641931</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323071>10.1161/CIRCRESAHA.123.323071</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37641931</guid>
<pubDate>Tue, 29 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Holger Lörchner</dc:creator>
<dc:creator>Laia Cañes Esteve</dc:creator>
<dc:creator>Maria Elisa Góes</dc:creator>
<dc:creator>Roxanne Harzenetter</dc:creator>
<dc:creator>Nathalie Brachmann</dc:creator>
<dc:creator>Praveen Gajawada</dc:creator>
<dc:creator>Stefan Günther</dc:creator>
<dc:creator>Nicolas Doll</dc:creator>
<dc:creator>Jochen Pöling</dc:creator>
<dc:creator>Thomas Braun</dc:creator>
<dc:date>2023-08-29</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Neutrophils for Revascularization Require Activation of CCR6 and CCL20 by TNFα</dc:title>
<dc:identifier>pmid:37641931</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323071</dc:identifier>
</item>
<item>
<title>Concomitant Coronary Atheroma Regression and Stabilization in Response to Lipid-Lowering Therapy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37640248/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230829180705&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Triple regression occurred in one third of AMI patients receiving high-intensity lipid-lowering therapy and was associated with alirocumab treatment, higher baseline lipid content and reduced cardiovascular events.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 20:S0735-1097(23)06468-9. doi: 10.1016/j.jacc.2023.08.019. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The frequency, characteristics and outcomes of patients treated with high-intensity lipid-lowering therapy and showing concomitant atheroma volume reduction, lipid content reduction, and increase in fibrous cap thickness (i.e., "triple regression") are unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study was designed to investigate rates, determinants and prognostic implications of triple regression in patients presenting with acute myocardial infarction (AMI) and treated with high-intensity lipid-lowering therapy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The PACMAN-AMI trial employed serial intravascular ultrasound, near-infrared spectroscopy, and optical coherence tomography to compare the effects of alirocumab vs. placebo in patients receiving high-intensity statin therapy. Triple regression was defined by the combined presence of percent atheroma volume (PAV) reduction, maximum lipid core burden index within 4 mm (maxLCBI<sub>4mm</sub>) reduction, and minimal fibrous cap thickness (FCT) increase. Clinical outcomes at one-year follow-up were assessed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Overall, 84 (31.7%) patients showed triple regression (40.8% in the alirocumab group vs. 23.0% in the placebo group, p=0.002). On-treatment low-density lipoprotein cholesterol levels were lower in patients with vs. without triple regression (between-group difference -27.1 [-37.7 to -16.6] mg/dl, p&lt;0.001). Triple regression was independently predicted by alirocumab treatment (odds-ratio [OR] 2.83, 95% confidence interval [CI] 1.57-5.16, p=0.001) and a higher baseline maxLCBI<sub>4mm</sub> (OR 1.03, 95%CI 1.01-1.06, p=0.013). The composite clinical endpoint of death, myocardial infarction and ischemia-driven revascularization occurred less frequently in patients with vs. without triple regression (8.3% vs. 18.2%, p=0.04).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Triple regression occurred in one third of AMI patients receiving high-intensity lipid-lowering therapy and was associated with alirocumab treatment, higher baseline lipid content and reduced cardiovascular events.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37640248/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829180705&v=2.17.9.post6+86293ac">37640248</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.019>10.1016/j.jacc.2023.08.019</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37640248</guid>
<pubDate>Mon, 28 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Flavio G Biccirè</dc:creator>
<dc:creator>Jonas Häner</dc:creator>
<dc:creator>Sylvain Losdat</dc:creator>
<dc:creator>Yasushi Ueki</dc:creator>
<dc:creator>Hiroki Shibutani</dc:creator>
<dc:creator>Tatsuhiko Otsuka</dc:creator>
<dc:creator>Ryota Kakizaki</dc:creator>
<dc:creator>Thomas M Hofbauer</dc:creator>
<dc:creator>Robert-Jan van Geuns</dc:creator>
<dc:creator>Stefan Stortecky</dc:creator>
<dc:creator>Georgios Cm Siontis</dc:creator>
<dc:creator>Sarah Bär</dc:creator>
<dc:creator>Jacob Lønborg</dc:creator>
<dc:creator>Dik Heg</dc:creator>
<dc:creator>Christoph Kaiser</dc:creator>
<dc:creator>David Spirk</dc:creator>
<dc:creator>Joost Daemen</dc:creator>
<dc:creator>Juan Iglesias</dc:creator>
<dc:creator>Stephan Windecker</dc:creator>
<dc:creator>Thomas Engstrøm</dc:creator>
<dc:creator>Irene Lang</dc:creator>
<dc:creator>Konstantinos C Koskinas</dc:creator>
<dc:creator>Lorenz Räber</dc:creator>
<dc:date>2023-08-28</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Concomitant Coronary Atheroma Regression and Stabilization in Response to Lipid-Lowering Therapy</dc:title>
<dc:identifier>pmid:37640248</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.019</dc:identifier>
</item>
<item>
<title>What Is a Normal Left Ventricular Ejection Fraction?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37639509/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230829180705&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Aug 29;148(9):750-752. doi: 10.1161/CIRCULATIONAHA.123.065791. Epub 2023 Aug 28.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37639509/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829180705&v=2.17.9.post6+86293ac">37639509</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065791>10.1161/CIRCULATIONAHA.123.065791</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37639509</guid>
<pubDate>Mon, 28 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Paul Heidenreich</dc:creator>
<dc:date>2023-08-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>What Is a Normal Left Ventricular Ejection Fraction?</dc:title>
<dc:identifier>pmid:37639509</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065791</dc:identifier>
</item>
<item>
<title>Response by Ostadal and Belohlavek to Letter Regarding Article, "Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock: Results of the ECMO-CS Randomized Clinical Trial"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37639508/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230829180705&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Aug 29;148(9):804. doi: 10.1161/CIRCULATIONAHA.123.065358. Epub 2023 Aug 28.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37639508/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829180705&v=2.17.9.post6+86293ac">37639508</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065358>10.1161/CIRCULATIONAHA.123.065358</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37639508</guid>
<pubDate>Mon, 28 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Petr Ostadal</dc:creator>
<dc:creator>Jan Belohlavek</dc:creator>
<dc:date>2023-08-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Response by Ostadal and Belohlavek to Letter Regarding Article, "Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock: Results of the ECMO-CS Randomized Clinical Trial"</dc:title>
<dc:identifier>pmid:37639508</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065358</dc:identifier>
</item>
<item>
<title>Letter by Ferreira Regarding Article, "Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock: Results of the ECMO-CS Randomized Clinical Trial"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37639506/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230829180705&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Aug 29;148(9):803. doi: 10.1161/CIRCULATIONAHA.122.063622. Epub 2023 Aug 28.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37639506/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829180705&v=2.17.9.post6+86293ac">37639506</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.122.063622>10.1161/CIRCULATIONAHA.122.063622</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37639506</guid>
<pubDate>Mon, 28 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Jorge Ferreira</dc:creator>
<dc:date>2023-08-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Ferreira Regarding Article, "Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock: Results of the ECMO-CS Randomized Clinical Trial"</dc:title>
<dc:identifier>pmid:37639506</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.122.063622</dc:identifier>
</item>
<item>
<title>Stages of Dismantling Structural Racism in Medicine: A Focus on Medical Training</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37639505/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230829180705&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Aug 29;148(9):800-802. doi: 10.1161/CIRCULATIONAHA.123.066131. Epub 2023 Aug 28.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37639505/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829180705&v=2.17.9.post6+86293ac">37639505</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066131>10.1161/CIRCULATIONAHA.123.066131</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37639505</guid>
<pubDate>Mon, 28 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Nisha Donthi</dc:creator>
<dc:creator>Catherine R Lucey</dc:creator>
<dc:creator>Michelle A Albert</dc:creator>
<dc:date>2023-08-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Stages of Dismantling Structural Racism in Medicine: A Focus on Medical Training</dc:title>
<dc:identifier>pmid:37639505</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066131</dc:identifier>
</item>
<item>
<title>Frailty and outcomes in heart failure patients from high-, middle- and low-Income countries</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37639487/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230829180705&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Frailty confers substantial incremental prognostic information to prognostic variables for predicting death and HF hospitalization. The relationship between frailty and these outcomes is consistent across countries at all income levels.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 28:ehad595. doi: 10.1093/eurheartj/ehad595. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: There is little information on the incremental prognostic importance of frailty beyond conventional prognostic variables in heart failure (HF) populations from different country income levels.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: 3429 adults with HF (age 61±14 years, 33% women) from 27 high-, middle- and low-income countries were prospectively studied. Baseline frailty was evaluated by the Fried index, incorporating handgrip strength, gait speed, physical activity, unintended weight loss and self-reported exhaustion. Mean left ventricular ejection fraction was 39±14% and 26% had New York Heart Association (NYHA) class III/IV symptoms. Participants were followed for a median (25th-75th percentile) 3.1 (2.0-4.3) years. Cox proportional hazards models for death and HF hospitalization adjusted for country income level; age; sex; education; HF etiology; left ventricular ejection fraction; diabetes; tobacco and alcohol use; NYHA functional class; HF medication use; blood pressure; hemoglobin, sodium and creatinine concentrations were performed. The incremental discriminatory value of frailty over and above the MAGGIC risk score was evaluated by the area under the receiver-operating characteristic curve.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: At baseline, 18% of participants were robust, 61% pre-frail and 21% frail. During follow-up, 565 (16%) participants died and 471 (14%) were hospitalized for HF. Respective adjusted hazard ratios [HRs (95% CI)] for death among the prefrail and frail were 1.59 (1.12-2.26) and 2.92 (1.99-4.27). Respective adjusted HRs (95% CI) for HF hospitalization were 1.32 (0.93-1.87) and 1.97 (1.33-2.91). Findings were consistent among different country income levels and by most subgroups. Adding frailty to the MAGGIC risk score improved the discrimination of future death and HF hospitalization.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Frailty confers substantial incremental prognostic information to prognostic variables for predicting death and HF hospitalization. The relationship between frailty and these outcomes is consistent across countries at all income levels.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37639487/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829180705&v=2.17.9.post6+86293ac">37639487</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad595>10.1093/eurheartj/ehad595</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37639487</guid>
<pubDate>Mon, 28 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Darryl P Leong</dc:creator>
<dc:creator>Philip Joseph</dc:creator>
<dc:creator>John J V McMurray</dc:creator>
<dc:creator>Jean Rouleau</dc:creator>
<dc:creator>Aldo P Maggioni</dc:creator>
<dc:creator>Fernando Lanas</dc:creator>
<dc:creator>Sanjib K Sharma</dc:creator>
<dc:creator>Julio Núñez</dc:creator>
<dc:creator>Bishav Mohan</dc:creator>
<dc:creator>Ahmet Celik</dc:creator>
<dc:creator>Jabir Abdullakutty</dc:creator>
<dc:creator>Okechukwu S Ogah</dc:creator>
<dc:creator>Lisa M Mielniczuk</dc:creator>
<dc:creator>Kumar Balasubramanian</dc:creator>
<dc:creator>Tara McCready</dc:creator>
<dc:creator>Alex Grinvalds</dc:creator>
<dc:creator>Salim Yusuf</dc:creator>
<dc:creator>P Joseph</dc:creator>
<dc:creator>G-CHF Investigators</dc:creator>
<dc:date>2023-08-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Frailty and outcomes in heart failure patients from high-, middle- and low-Income countries</dc:title>
<dc:identifier>pmid:37639487</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad595</dc:identifier>
</item>
<item>
<title>Third generation PCSK9-Inhibitors</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37639486/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230829180705&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 28:ehad566. doi: 10.1093/eurheartj/ehad566. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37639486/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829180705&v=2.17.9.post6+86293ac">37639486</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad566>10.1093/eurheartj/ehad566</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37639486</guid>
<pubDate>Mon, 28 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Ulrich Laufs</dc:creator>
<dc:creator>Matthias Blüher</dc:creator>
<dc:creator>Berend Isermann</dc:creator>
<dc:date>2023-08-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Third generation PCSK9-Inhibitors</dc:title>
<dc:identifier>pmid:37639486</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad566</dc:identifier>
</item>
<item>
<title>Emery-Dreifuss Muscular Dystrophy 1 is associated with high risk of malignant ventricular arrhythmias and end-stage heart failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37639473/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230829180705&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Male EMD variant-carriers have a risk of progressive heart failure and ventricular arrhythmias similar to that of male LMNA variant-carriers. Early implantable cardioverter defibrillator implantation and heart failure drug therapy should be considered in male EMD variant-carriers with cardiac disease.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 28:ehad561. doi: 10.1093/eurheartj/ehad561. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Emery-Dreifuss muscular dystrophy (EDMD) is caused by variants in EMD (EDMD1) and LMNA (EDMD2). Cardiac conduction defects and atrial arrhythmia are common to both, but LMNA variants also cause end-stage heart failure (ESHF) and malignant ventricular arrhythmia (MVA). This study aimed to better characterise the cardiac complications of EMD variants.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Consecutively referred EMD variant-carriers were retrospectively recruited from 12 international cardiomyopathy units. MVA and ESHF incidence in male and female variant-carriers was determined. Male EMD variant-carriers with a cardiac phenotype at baseline (EMDCARDIAC) were compared to consecutively recruited male LMNA variant-carriers with a cardiac phenotype at baseline (LMNACARDIAC).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Longitudinal follow-up data were available for 38 male and 21 female EMD variant-carriers (mean [SD] ages 33.4 [13.3] and 43.3 [16.8] years, respectively). Nine (23.6%) males developed MVA and five (13.2%) developed ESHF during a median [IQR] follow-up of 65.0 [24.3, 109.5] months. No female EMD variant-carrier had MVA or ESHF, but nine (42.8%) developed a cardiac phenotype at a median [IQR] age of 58.6 [53.2, 60.4] years. Incidence rates for MVA were similar for EMDCARDIAC and LMNACARDIAC (4.8 and 6.6 per 100 person-years, respectively; log-rank p = 0.49). Incidence rates for ESHF were 2.4 and 5.9 per 100 person-years for EMDCARDIAC and LMNACARDIAC, respectively (log-rank p = 0.09).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Male EMD variant-carriers have a risk of progressive heart failure and ventricular arrhythmias similar to that of male LMNA variant-carriers. Early implantable cardioverter defibrillator implantation and heart failure drug therapy should be considered in male EMD variant-carriers with cardiac disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37639473/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829180705&v=2.17.9.post6+86293ac">37639473</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad561>10.1093/eurheartj/ehad561</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37639473</guid>
<pubDate>Mon, 28 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Douglas E Cannie</dc:creator>
<dc:creator>Petros Syrris</dc:creator>
<dc:creator>Alexandros Protonotarios</dc:creator>
<dc:creator>Athanasios Bakalakos</dc:creator>
<dc:creator>Jean-François Pruny</dc:creator>
<dc:creator>Raffaello Ditaranto</dc:creator>
<dc:creator>Cristina Martinez-Veira</dc:creator>
<dc:creator>Jose M Larrañaga-Moreira</dc:creator>
<dc:creator>Kristen Medo</dc:creator>
<dc:creator>Francisco José Bermúdez-Jiménez</dc:creator>
<dc:creator>Rabah Ben Yaou</dc:creator>
<dc:creator>France Leturq</dc:creator>
<dc:creator>Ainhoa Robles Mezcua</dc:creator>
<dc:creator>Chiara Marini-Bettolo</dc:creator>
<dc:creator>Eva Cabrera</dc:creator>
<dc:creator>Chloe Reuter</dc:creator>
<dc:creator>Javier Limeres Freire</dc:creator>
<dc:creator>José F Rodríguez-Palomares</dc:creator>
<dc:creator>Luisa Mestroni</dc:creator>
<dc:creator>Matthew R G Taylor</dc:creator>
<dc:creator>Victoria N Parikh</dc:creator>
<dc:creator>Euan A Ashley</dc:creator>
<dc:creator>Roberto Barriales-Villa</dc:creator>
<dc:creator>Juan Jiménez-Jáimez</dc:creator>
<dc:creator>Pablo Garcia-Pavia</dc:creator>
<dc:creator>Philippe Charron</dc:creator>
<dc:creator>Elena Biagini</dc:creator>
<dc:creator>José M García Pinilla</dc:creator>
<dc:creator>John Bourke</dc:creator>
<dc:creator>Konstantinos Savvatis</dc:creator>
<dc:creator>Karim Wahbi</dc:creator>
<dc:creator>Perry M Elliott</dc:creator>
<dc:date>2023-08-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Emery-Dreifuss Muscular Dystrophy 1 is associated with high risk of malignant ventricular arrhythmias and end-stage heart failure</dc:title>
<dc:identifier>pmid:37639473</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad561</dc:identifier>
</item>
<item>
<title>Frailty: A new Vital Sign in Heart Failure Comes of age</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37639470/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230829180705&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 28:ehad559. doi: 10.1093/eurheartj/ehad559. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37639470/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829180705&v=2.17.9.post6+86293ac">37639470</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad559>10.1093/eurheartj/ehad559</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37639470</guid>
<pubDate>Mon, 28 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Finlay A McAlister</dc:creator>
<dc:date>2023-08-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Frailty: A new Vital Sign in Heart Failure Comes of age</dc:title>
<dc:identifier>pmid:37639470</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad559</dc:identifier>
</item>
<item>
<title>Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: the LIBerate-HeFH trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37639462/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230829180705&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Lerodalcibep, a novel anti-PCSK9 small binding protein dosed monthly as an alternative to monoclonal antibodies, significantly reduced LDL-C in subjects with HeFH with a safety profile similar to placebo.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 28:ehad596. doi: 10.1093/eurheartj/ehad596. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Lerodalcibep, a novel small recombinant fusion protein of a PCSK9-binding domain (adnectin) and human serum albumin demonstrated highly effective low-density lipoprotein cholesterol (LDL-C) reduction with monthly 300 mg in 1.2 ml SC dosing in Phase 2. In this global Phase 3 trial, the safety and efficacy of lerodalcibep was evaluated in heterozygous familial hypercholesterolaemia (HeFH) patients requiring additional LDL-C lowering.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Patients were randomized 2:1 to monthly SC injections of either lerodalcibep 300 mg or placebo for 24 weeks. The primary efficacy endpoints were the percent change from baseline in LDL-C at Week 24 and the mean of Weeks 22 and 24.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In 478 randomized subjects [mean age (range); 53 (18-80) years, 51.7% female, mean (SD) baseline LDL-C 3.88 (1.66) mmol/L] lerodalcibep reduced LDL-C, compared to placebo by an absolute amount of 2.08 (0.11) mmol/L [LS mean(SE); 95% CI -2.30 to -1.87] with a percentage difference of -58.61 (3.25)% at Week 24 and by 2.28 (0.10) mmol/L (95% CI -2.47 to -2.09) with a percentage difference of -65.0 (2.87)% at the mean of Weeks 22 and 24 (P &lt; 0.0001 for all). With lerodalcibep, 68% of subjects achieved both a reduction in LDL-C ≥ 50% and the recommended ESC LDL-C targets during the study. Except for mild injection site reactions, treatment-emergent adverse events were similar between lerodalcibep and placebo.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Lerodalcibep, a novel anti-PCSK9 small binding protein dosed monthly as an alternative to monoclonal antibodies, significantly reduced LDL-C in subjects with HeFH with a safety profile similar to placebo.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37639462/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829180705&v=2.17.9.post6+86293ac">37639462</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad596>10.1093/eurheartj/ehad596</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37639462</guid>
<pubDate>Mon, 28 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Frederick Raal</dc:creator>
<dc:creator>Nyda Fourie</dc:creator>
<dc:creator>Russell Scott</dc:creator>
<dc:creator>Dirk Blom</dc:creator>
<dc:creator>Matthys De Vries Basson</dc:creator>
<dc:creator>Meral Kayikcioglu</dc:creator>
<dc:creator>Kate Caldwell</dc:creator>
<dc:creator>David Kallend</dc:creator>
<dc:creator>Evan Stein</dc:creator>
<dc:creator>LIBerate-HeFH Investigators</dc:creator>
<dc:date>2023-08-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: the LIBerate-HeFH trial</dc:title>
<dc:identifier>pmid:37639462</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad596</dc:identifier>
</item>
<item>
<title>Long-Term Efficacy and Safety of Mavacamten in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37639276/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230829180705&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Aug 28. doi: 10.1001/jamacardio.2023.3357. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37639276/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829180705&v=2.17.9.post6+86293ac">37639276</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.3357>10.1001/jamacardio.2023.3357</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37639276</guid>
<pubDate>Mon, 28 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Sharlene M Day</dc:creator>
<dc:creator>James E Udelson</dc:creator>
<dc:creator>Robert O Bonow</dc:creator>
<dc:date>2023-08-28</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Long-Term Efficacy and Safety of Mavacamten in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy</dc:title>
<dc:identifier>pmid:37639276</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.3357</dc:identifier>
</item>
<item>
<title>Mavacamten for Obstructive Hypertrophic Cardiomyopathy in China</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37639265/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230829180705&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Aug 28. doi: 10.1001/jamacardio.2023.3045. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37639265/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829180705&v=2.17.9.post6+86293ac">37639265</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.3045>10.1001/jamacardio.2023.3045</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37639265</guid>
<pubDate>Mon, 28 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Milind Y Desai</dc:creator>
<dc:date>2023-08-28</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Mavacamten for Obstructive Hypertrophic Cardiomyopathy in China</dc:title>
<dc:identifier>pmid:37639265</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.3045</dc:identifier>
</item>
<item>
<title>Effect of Mavacamten on Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy: The EXPLORER-CN Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37639259/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230829180705&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Mavacamten significantly improved Valsalva LVOT gradient vs placebo for Chinese patients. All secondary efficacy end points were also improved. Mavacamten was well tolerated with no new safety signals. This study supports the efficacy and safety of mavacamten in diverse populations, including Chinese patients.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Aug 28. doi: 10.1001/jamacardio.2023.3030. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Mavacamten has shown clinical benefits in global studies for patients with obstructive hypertrophic cardiomyopathy (oHCM), but evidence in the Asian population is lacking.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To evaluate the safety and efficacy of mavacamten compared with placebo for Chinese patients with symptomatic oHCM.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This phase 3, randomized, double-blind, placebo-controlled clinical trial was conducted at 12 hospitals in China. Between January 4 and August 5, 2022, patients with oHCM and a left ventricular outflow tract (LVOT) gradient of 50 mm Hg or more and New York Heart Association (NYHA) class II or III symptoms were enrolled and received treatment for 30 weeks.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: Patients were randomized 2:1 to receive mavacamten (starting at 2.5 mg once daily) or placebo for 30 weeks.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary end point was change in Valsalva LVOT peak gradient from baseline to week 30. Left ventricular outflow tract gradients and left ventricular ejection fraction (LVEF) were assessed by echocardiography, while left ventricular mass index (LVMI) was determined by cardiac magnetic resonance imaging. Analysis was performed on an intention-to-treat basis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 81 patients (mean [SD] age, 51.9 [11.9] years; 58 men [71.6%]) were randomized. Mavacamten demonstrated a significant improvement in the primary end point compared with placebo (least-squares mean [LSM] difference, -70.3 mm Hg; 95% CI, -89.6 to -50.9 mm Hg; 1-sided P &lt; .001). Similar trends were demonstrated for resting LVOT peak gradient (LSM difference, -55.0 mm Hg; 95% CI, -69.1 to -40.9 mm Hg). At week 30, more patients receiving mavacamten than placebo achieved a Valsalva LVOT peak gradient less than 30 mm Hg (48.1% [26 of 54] vs 3.7% [1 of 27]), less than 50 mm Hg (59.3% [32 of 54] vs 7.4% [2 of 27]), and NYHA class improvement (59.3% [32 of 54] vs 14.8% [4 of 27]). Greater improvements were also observed with mavacamten regarding the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (LSM difference, 10.2; 95% CI, 4.4-16.1), N-terminal pro-B-type natriuretic peptide level (proportion of geometric mean ratio, 0.18; 95% CI, 0.13-0.24), high-sensitivity cardiac troponin I level (proportion of geometric mean ratio, 0.34; 95% CI, 0.27-0.42), and LVMI (mean difference, -30.8 g/m2; 95% CI, -41.6 to -20.1 g/m2). Safety and tolerability were similar between mavacamten and placebo. No patients experienced LVEF less than 50%.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Mavacamten significantly improved Valsalva LVOT gradient vs placebo for Chinese patients. All secondary efficacy end points were also improved. Mavacamten was well tolerated with no new safety signals. This study supports the efficacy and safety of mavacamten in diverse populations, including Chinese patients.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05174416.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37639259/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829180705&v=2.17.9.post6+86293ac">37639259</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.3030>10.1001/jamacardio.2023.3030</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37639259</guid>
<pubDate>Mon, 28 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Zhuang Tian</dc:creator>
<dc:creator>Liwen Li</dc:creator>
<dc:creator>Xiaoyan Li</dc:creator>
<dc:creator>Jian'an Wang</dc:creator>
<dc:creator>Qing Zhang</dc:creator>
<dc:creator>Zhanquan Li</dc:creator>
<dc:creator>Daoquan Peng</dc:creator>
<dc:creator>Ping Yang</dc:creator>
<dc:creator>Wei Ma</dc:creator>
<dc:creator>Fang Wang</dc:creator>
<dc:creator>Wei Jin</dc:creator>
<dc:creator>Xiang Cheng</dc:creator>
<dc:creator>Jing Sun</dc:creator>
<dc:creator>Yiqun Fu</dc:creator>
<dc:creator>Cheng Lyu</dc:creator>
<dc:creator>Shuyang Zhang</dc:creator>
<dc:date>2023-08-28</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Effect of Mavacamten on Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy: The EXPLORER-CN Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:37639259</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.3030</dc:identifier>
</item>





























</channel>
</rss>